attomarker

About

Revolutionising Diagnostics with Attomarker

The Challenge

For centuries, doctors have relied on symptoms to diagnose illnesses, but with over 4,000 diseases and under 400 symptom terms*, misdiagnosis and delayed treatment are common. Laboratory tests have helped, but results often take too long to reach clinicians—by which time treatment decisions may have already been made.Speed matters. In conditions like sepsis, a delay of even a few hours can be fatal. Yet for many other conditions, too, the ability to get fast, accurate, multi-dimensional results at the point of care is key to better treatment and improved outcomes.

*https://www.nature.com/articles/ncomms5212

7 reasons

The Solution

Attomarker is transforming diagnostics with its ground breaking biomarker technology, delivering lab-quality results in just 7–10 minutes. By measuring multiple biomarkers from a single finger prick of blood, our technology enables a more personalised, data-driven approach to healthcare.

Our unique gold nanoparticle technology provides fully quantitative results, ensuring higher accuracy than traditional rapid tests. With AI-driven analysis, Attomarker’s platform can detect patterns across multiple biomarkers, offering a deeper understanding of disease progression.

How Attomarker is Changing Diagnostics: 

  • Faster Diagnosis & Treatment – Results in minutes, ensuring clinicians can act immediately.
  • Comprehensive Testing – Multi-biomarker analysis for a detailed health profile, covering infections, fertility, liver health, and chronic diseases.
  • AI-Powered Precision – Enhances diagnostic accuracy, reducing misdiagnosis and unnecessary treatments.
  • Point-of-Care Accessibility – Testing can be done in clinics, pharmacies, workplaces, and even at home, removing the reliance on central labs.
  • Cost-Effective & Scalable – Reduces the need for multiple hospital visits, saving time and healthcare costs.

Attomarker is setting a new global standard for rapid, personalised diagnostics, ensuring that healthcare professionals have the right information, at the right time, to deliver better patient care.

The Company

Attomarker is a British company, founded in 2008 as a spin-out from Professor Andrew Shaw’s research group at the University of Exeter. Our award-winning nanophotonic technology enables fast, reliable, and personalised diagnostics, revolutionising the way diseases are detected and managed.

We believe that new health challenges demand innovative solutions, and we are dedicated to delivering gold-standard, rapid tests that empower clinicians and patients alike. Our mission is to make high-quality diagnostics accessible to all, bridging the gap between laboratory precision and real-world healthcare needs.

Leadership

Dr Jonathan Snicker

Executive Chair and Chief Strategy Officer

20+ years’ experience in variety of Board and Executive roles spanning, business development, philanthropy, university academia, strategic, political, comms and funding advisory.

Prof. Andrew Shaw

CEO & Founder

Attomarker is Prof Shaw’s second spinout company, the first having been sold for $8M. He will move to Chief Scientist when the next round is closed.

Guy Pengelly

Sakura Holloway 

NED, BIF Opportunities LP

Sakura represents Future Planet Capital as Portfolio Manager for their BIF Opportunities Fund, a specialist Life Sciences and AgTech venture capital fund investing in UK university spinouts at Series A/B stage.

Sandy Primrose

NED

Experienced Biotech entrepreneur as Chair and Director for many companies leading to trade sales

Yves Le Goff

Strategic Adviser and CCO, EU Markets

Yves co-led Attomarker’s GBP1.5m Future Fund 2020 funding round. He is a former investment banker (Goldman Sachs, Credit Suisse) and early-stage investor

Robert Warner

CFO

Chartered Accountant from KPMG, with 20 years’ experience as a commercial CFO, gained across a variety of rapid-scale international businesses in diverse sectors

Chandru R. Chandrasekar

Director of International Development

Chandru is an investor and former orthopaedic surgeon with deep connections in India and Singapore, with a mission to nurture sustainable technology platforms at ‘India Scale, India Price’.

Steve Brine

Advisor

Former MP, Health Minister and Chair of the cross-party Commons Health Select Committee, Steve is an authoritative voice on public health, healthcare innovation, and the prevention of ill health.

Shivali Kohli

Director of Products

With a PhD in neuropharmacology and 10+ years in scientific research at leading universities, she brings a wealth of experience in project and team management.

Philip James-Pemberton

Director of Research

Philip James-Pemberton leads the development of innovative diagnostic technologies. With a background in biomedical research and extensive experience in nanophotonic testing, he specialises in translating cutting-edge science into practical healthcare solutions. Philip plays a key role in advancing rapid, precise diagnostics for real-world applications.

Join the Team

If you are interested in joining the team please send a copy of your CV and tell us what you are interested in to: info@attomarker.com.